Pyrexia of Unknown Origin: An Atypical Presentation of Hepatic Hemangioma

Gunjan Desai, MS, MRCS, FMAS, DNB1  Dattaraj Budkule, DNB2  Prasad Pande, MS, FMAS, DNB1  Prasad Wagle, MS3

1 Department of Surgical Gastroenterology, MGM New Bombay Hospital, Navi Mumbai, Maharashtra, India  
2 Department of General Surgery, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India  
3 Department of Surgical Gastroenterology, Lilavati Hospital, Mumbai, Maharashtra, India

Surg J 2020;6:e180–e184.

Pyrexia of unknown origin (PUO) has perplexed clinicians since its first description in 1961 by Petersdorf and Beeson. They defined PUO as fever above 38°C or 101°F for longer than 3 weeks without an established diagnosis after a week of inpatient investigations.1 Over years, its causes have been identified as infective, of which tuberculosis is the most common cause in India, inflammatory, malignant, rare causes such as Kikuchi disease, adrenal insufficiency, biliary cholangitis, and finally idiopathic, which accounts for up to 1.6% cases.2 Hepatic hemangioma (HH) is a very rare cause of PUO with only a few case reports describing this association. It is not routinely considered in the differential diagnosis of PUO.3–5 HH is the most common benign hepatic tumor.6 It is usually asymptomatic, being incidentally diagnosed, or may present with pain and/or compressive symptoms. PUO is a rare presenting feature of HH.3–5 We present a case of giant HH presenting as PUO, describe its management, and review the literature in brief.

Case Report

A 38 years old lady with no comorbidities presented to the surgical gastroenterology department of a tertiary care center with intermittent low-grade fever without chills or rigors for 1 month. It was associated with right upper abdominal discomfort. She had no other symptoms, no history of travel, contact with pets; she had no tattoos and no history of recreational drug use, alcohol, or smoking. She was hemodynamically stable with nontender hepatomegaly 4 cm below the right costal margin. Rest of the abdominal and general examination was normal. Respiratory, cardiovascular, and central nervous system examination was also normal.

Address for correspondence Gunjan Desai, MS, MRCS, FMAS, DNB, Department of Surgical Gastroenterology, MGM New Bombay Hospital, 1301, Building 6, Kesar Harmony Society, Sector 6, Kharghar, Navi Mumbai, Maharashtra, India 410210 (e-mail: dsshlsh@gmail.com).

Keywords
► liver tumor  
► transarterial embolization  
► liver resection

Abstract

Pyrexia of unknown origin (PUO) has been a diagnostic challenge for decades. Hepatic hemangioma (HH) is not a common differential diagnosis of PUO. It is the most common benign hepatic tumor, commonly asymptomatic and incidentally detected, or can present with vague abdominal pain. PUO is a rare presenting feature. We describe a case of 38-year-old lady presenting with PUO. With no other identifiable source of fever despite exhaustive investigations, a giant hemangioma in right lobe of liver detected on abdominal ultrasonography was deemed to be the cause of PUO. The patient had sudden decrease in hemoglobin while undergoing workup, which on imaging showed a bleeding hemangioma and right hepatectomy was performed. Patient had an uneventful recovery and her PUO also resolved after surgery. HH should be considered a rare diagnosis of exclusion for PUO after a standard algorithmic approach does not reveal any other cause.

License terms

Copyright © 2020 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA  
Tel: +1(212) 760-0888.  

DOI https://doi.org/10.1055/s-0040-1721428.  
ISSN 2378-5128.
Complete hemogram, liver, and renal function tests were normal. Erythrocyte sedimentation rate was 52 mm/h (normal—up to 32 mm/h) and C-reactive protein was 12 mg/L (normal up to 5 mg/L). She was worked up exhaustively and meticulously for PUO and infective, inflammatory, and autoimmune etiologies were ruled out.

During this period, her hemoglobin dropped from 12.6 g/dL to 9 g/dL, without any hemodynamic instability or overt signs of bleeding. Abdominal ultrasonography (USG) showed a large hyperechoic lesion in the right lobe of liver with internal vascularity. Contrast-enhanced computed tomography of the abdomen showed a large hypodense lesion involving hepatic segment 5, 6, 7, and 8 with areas of hemorrhage and thrombus in the lesion in noncontrast phase with centripetal contrast enhancement in arterial phase and delayed washout with contrast pooling in the lesion (►Fig. 1). A positron emission tomography scan was also performed that did not reveal any focus of infection.

In view of symptomatic giant HH and suspected hemorrhage, right hepatectomy was planned, with functional liver remnant of 40%. Preoperative bland arterial embolization was done 1 day prior to surgery. Right hepatectomy was performed with intermittent selective right Glissonian pedicle occlusion and a combination of posterior and anterior hanging approach (►Figs. 2, 3). The procedure was uneventful with a blood loss of 300 mL.

The patient recovered uneventfully and was afebrile after surgery. She was discharged on postoperative day 6. Histopathology revealed a cavernous hemangioma with areas of thrombosis and hemorrhage. The patient is asymptomatic at 9 months follow-up.

Discussion

PUO has been a diagnostic challenge for decades. There have been frequent changes in its definition, especially with regard to the temporal criteria, which has changed from 1 week of inpatient investigation in its first definition to 3 days of outpatient or inpatient investigations by Durack and Street to the latest defined “pragmatic investigation period” by Knockaert et al and structured diagnostic checklist without any time frame.1,7,8 Across the literature, the key aspect is presence of a structured diagnostic algorithm for cases with PUO to reduce the number of undiagnosed and idiopathic cases. Our stepwise approach to PUO is highlighted in ►Fig. 4. Giant HH as a cause of PUO is a diagnosis of exclusion as established in our case after thorough and exhaustive attempt to rule out common causes of PUO.

HH is the most common benign hepatic tumor, constituting ~70% of them.4,5 HHs are blood-filled cavities within the liver parenchyma lined by endothelial cells fed by a branch of hepatic artery.5,6 The incidence of HH is reported to be 0.4 to 20%.4,5,9 They have female predilection 5:1. The mean age of presentation is 30 to 50 years.4,9 They vary in size from few millimeters to 3 cm (small), 3 to 10 cm (medium), and more
than 10 cm (giant hemangiomas). The exact pathophysiology is poorly understood and congenital factors, abnormal vasculogenesis, and hormonal factors (estrogen dependence) play some role.\textsuperscript{4,10}

HHs are usually small, solitary, in the right lobe and most commonly incidentally detected. Less common symptoms are vague abdominal discomfort, right upper quadrant pain, anorexia, nausea, vomiting, and, rarely, PUO.\textsuperscript{4,10,11} HH can present with complications such as compression (gastric outlet obstruction, jaundice), rupture, bleeding or coagulopathy. (Kasabach–Merritt syndrome due to exposure of platelets to the subendothelial collagen in hemangiomas leads

---

**Fig. 4** Our stepwise approach to diagnosis of pyrexia of unknown origin.

**Stepwise approach to pyrexia of unknown origin**

**STEP 1: History and examination**
- **History** - Chest (cough, dyspnea, chest pain, throat irritation), Abdomen (alteration in bowel and bladder habits, abdominal pain, vomiting, lump, jaundice), Central nervous system (headache, dizziness, retro-orbital pain), Rash, anorexia, weight loss, joint pains, oral and dental complaints, Swelling anywhere in body, itching, edema, Recent travel, exposure to pets, tattoos, recreational drug use, occupational history

- **Examination** - Anemia, lymphadenopathy, organomegaly, joint tenderness, All systems examination

**STEP 2: Biochemical and microbiological investigations**
- Cytopenia, Anemia, liver and kidney function tests, thyroid profile, malarial parasite, dengue antigen, viral markers for hepatitis and acquired immune deficiency syndrome, mantoux test, blood culture, urine routine, microscopy and culture, Stool for occult blood, routine, microscopy, throat swab, Coomb’s test, anti-nuclear antibody, rheumatoid factor, Erythrocyte sedimentation rate, C-reactive protein and procalcitonin

**STEP 3: Radiological and nuclear imaging**
- Chest roentgenogram, Ultrasound abdomen AND/OR Computed tomography of chest, abdomen and pelvis Positron emission tomography scan

**STEP 4: Endoscopies and site specific evaluation**
- (This is based on above investigations as well as any indicators on history and examination to a specific site)
to their activation and consumption, causing thrombocytopenia and purpuras.\textsuperscript{12}

The initial diagnostic modality is usually USG that shows a homogenous hyperechoic lesion with sharp margins and acoustic enhancement.\textsuperscript{8} However, inhomogeneous lesions with mixed echogenicity can be seen with fibrosis, thrombosis, or hemorrhage.\textsuperscript{6} USG with Doppler shows no perilesional vascularity unlike in hepatocellular carcinomas and metastatic lesions. On liver protocol computed tomography, HH appears as a well-defined hypodense lesion with peripheral nodular enhancement with progressive centripetal homogenous contrast filling with slow washout, unlike that in malignant lesion where there is a rapid washout.\textsuperscript{5,6}

Magnetic resonance imaging with diagnostic sensitivity and specificity of more than 90\% shows characteristic well-demarcated homogenous lesion, hypointense in T1-weighted images, and hyperintense on T2-weighted images, with persistent contrast enhancement on delayed phase imaging.\textsuperscript{6} Technetium 99-labeled red blood cell pool scintigraphy is 100\% specific, which shows perfusion/blood pool mismatch, that is, decreased perfusion on early dynamic images and a gradual increase in activity on blood pool images over time. Biopsy is not performed due to high risk of hemorrhage as well as its low yield.\textsuperscript{11,12}

Small HH can be managed conservatively. Surgery is considered in cases of rapid increase in size, intractable pain, giant HH or complications such as rupture, bleeding, or Kasabach–Merritt syndrome.\textsuperscript{5,6,12} In a study, persistent abdominal symptoms were the most common indication for surgery.\textsuperscript{13} A nationwide survey in Japan, in patients with ≤5 cm hemangioma, surgical resection was indicated when a malignant tumor cannot be ruled out.\textsuperscript{14} Surgical options include enucleation and formal hepatectomy. Preoperative embolization helps decrease the size of the lesion and reduces intraoperative blood loss.\textsuperscript{9} Surgery can be combined with percutaneous or laparoscopic radiofrequency ablation. Nonsurgical options include radiotherapy, usually 15 to 30 Gray, 15 to 22 fractions over 3 weeks. Some role of chemotherapy, although controversial, has also been demonstrated with bleomycin, etoposide, cisplatin.\textsuperscript{5,9} In case of giant hemangiomas, or hemangiomas involving both hepatic lobes, liver transplant can be considered.\textsuperscript{6}

Table 1 summarizes the recent literature of HH presenting as PUO.\textsuperscript{9,11,15–17} This atypical presentation of HH was first described by Schumacker in 1942, where one out of 66 surgically treated liver hemangioma patients had fever.\textsuperscript{18} Although not certain, Kupffer cells are believed to be the source of endogenous pyrogens that can cause persistent fever in HH. A case of PUO due to giant HH managed successfully with right hepatectomy is described.\textsuperscript{9} In contrast, another report described successful management of HH presenting as PUO with conservative management.\textsuperscript{11}

### Conclusion

PUO needs a stepwise algorithmic approach to diagnosis and institutional protocols would be helpful to take into consideration the demographic conditions affecting the diagnosis. HH as a cause of PUO is a diagnosis of exclusion as these are rarely symptomatic even when they are giant and should be considered cause of PUO after exhaustive attempts to rule out other causes. Surgical excision needs to be considered as a treatment of PUO in these cases.

- **Grants/Other Financial Support**
  - Financial Support None.

- **Compliance with Ethical Standards**

  **Ethics Statement**
  - The study was performed after the approval of research protocols by the Ethics Committee of Lilavati Hospital and Research Centre in accordance with international agreements (World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects,” amended in October 2013, www.wma.net)

  **Informed Consent**
  - Written informed consent was obtained from the patient involved in the study.

| Number | Authors | Age  | Sex | Symptoms | Duration | Treatment |
|--------|---------|------|-----|----------|----------|-----------|
| 1      | Kathleen Hopkins\textsuperscript{9} | 46   | Female | Right upper quadrant abdominal pain, fever, chills, night sweats, anorexia, cough | 1 mo | Right hepatectomy |
| 2      | Lee et al\textsuperscript{11} | 37   | Female | Fever | 15 d | Observation |
| 3      | van Gorcum et al\textsuperscript{15} | 41   | Female | Fever, night sweats, malaise, pain, weight loss | – | Surgical excision |
| 4      | Pandit et al\textsuperscript{16} | 49   | Female | Fever | 3 mo | Laparoscopic-assisted left lateral segmentectomy |
| 5      | Liu et al\textsuperscript{17} | 33   | Male | Fever | 2 mo | Right trisectionectomy |
| 6      | Our case | 30   | Female | Fever | 1 mo | Right hepatectomy |
Author Contributions
Gunjan Desai was involved in collecting data, analysis of data, preparing the initial draft of the manuscript, critical revision of the manuscript for intellectual content, technical support, material support, study supervision
Dattaraj Budkule was involved in collecting data, analysis of data, preparing the initial draft of the manuscript
Prasad Pande was involved in critical revision of the manuscript for intellectual content, technical support, material support, study supervision
Prasad Wagle was involved in study concept, critical revision of the manuscript for intellectual content, administrative, technical support, material support, study supervision.

Financial Disclosure
The authors declare that this study has received no financial support.

Pyrexia of Unknown Origin
An atypical presentation of a giant hepatic hemangioma.

Conflict of Interest
The authors declare that they have no conflict of interest.

References
1 Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961;40(01):1–30
2 Rupali P, Garg D, Abraham O, David T, Surekha V. Etiology of classic fever of unknown origin among immunocompetent adults from India. Open Forum Infect Dis 2016;3(01):
3 Unger M, Karanikas G, Kirschbaum A, Winkler S, Aletaha D. Fever of unknown origin (FUO) revised. Wien Klin Wochenschr 2016;128(21–22):796–801
4 European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol 2016;65(02):386–398
5 Toro A, Mahfouz AE, Ardiri A, et al. What is changing in indications and treatment of hepatic hemangiomas. A review. Ann Hepatol 2014;13(04):327–339
6 Montero L. Review Article: A Giant Hepatic Hemangioma. Gastroenterol Hepatol Open Access 2017;7(05):00251. Doi: 10.15406/ghoa.2017.07.00251
7 Durack DT, Street AC. Fever of unknown origin–reexamined and redefined. Curr Clin Top Infect Dis 1991;11:35–51
8 Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown origin in adults: 40 years on. J Intern Med 2003;253(03):263–275
9 Kathleen Hopkins RJB. Hepatic hemangioma: an unusual cause of fever of unknown origin. Can J Gastroenterol 1990;4(06):227–229
10 Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006;1089(01):228–236
11 Lee CW, Chung YH, Lee GC, Kim JY, Lee JS. A case of giant hemangioma of the liver presenting with fever of unknown origin. J Korean Med Sci 1994;9(02):200–204
12 Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001;112(04):851–862
13 Miura JT, Amini A, Schmocker R, et al. Surgical management of hepatic hemangiomas: a multi-institutional experience. HPB (Oxford) 2014;16(10):924–928
14 Sakamoto Y, Kokudo N, Watadani T, Shibahara J, Yamamoto M, Yamaue H. Japanese Society of Hepato-Biliary-Pancreatic Surgery. Proposal of size-based surgical indication criteria for liver hemangioma based on a nationwide survey in Japan. J Hepatobiliary Pancreat Sci 2017;24(07):417–425
15 van Gorcum M, van Buuren HR, Hussain SM, Zondervan PE, IJzermans JN, de Man RA. [Fever as a sign of inflammatory syndrome in a female patient with hepatic haemangioma]. Ned Tijdschr Geneeskd 2005;149(22):1227–1230
16 Pandit N, Awale L, Chaudhary S, Jaiswal LS. Fever of unknown origin: a rare presentation of giant hepatic hemangioma. J Surg Case Rep 2018;2018(06):rjy143
17 Liu X, Yang Z, Tan H, Zhou W, Su Y. Fever of unknown origin caused by giant hepatic hemangioma. J Gastrointest Surg 2018;22(02):366–367
18 Schumacker HB Jr. Hemangioma of the liver. Surgery 1942;11:209–222